MeSH D009396 - wilms tumor
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Doxorubicin | Doxorubicin | 1995-07-28 | |||
| Doxorubicin | Myocet (previously Myocet) | 2000-07-13 | ||||
| Vincristine | Vincasar | 1987-07-17 | ||||
| Vincristine | Vincristine | 1999-09-01 | ||||
| Mylan | Doxorubicin | Doxorubicin | 2011-10-28 | |||
| Pfizer | Doxorubicin | Adriamycin | 1991-01-30 | |||
| Doxorubicin | Doxorubicin | 1982-01-01 | ||||
| Eli Lilly | Vincristine | Oncovin | 1982-01-01 | |||
| Dr Reddys Laboratories | Doxorubicin | Doxorubicin | 2017-05-15 | |||
| Zydus Therapeutics | Doxorubicin | Doxorubicin | 2020-09-10 | |||
| Sun Pharmaceutical Industries | Doxorubicin | Doxorubicin | 2012-02-15 | |||
| Hospira | Vincristine | Vincristine | 1988-04-19 | |||
| Amneal Pharmaceuticals | Doxorubicin | Doxorubicin | 2017-02-17 | |||
| Bristol Myers Squibb | Doxorubicin | Rubex | 1989-04-13 | |||
| Vincristine | Vincrex | 1988-07-12 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
37%11/30
Phase 2
24%9/38
Phase 3
50%9/18
Approved: 4Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use